CompletedNCT00900952Updated Oct 9, 2009

Epidemiologic Study Evaluating Infections in Elderly Patients

An observational study in Infection, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer. Completed at 1 site in Spain. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2009-10-09.

Sponsored by Wyeth is now a wholly owned subsidiary of Pfizer · Observational

Study type: Observational
Model: Cohort
Time perspective: Prospective
Enrollment: 240
Ages: 65 Years and older
Sex: All

Study summary

The purpose of this observational study is to assess the prevalence and demographic and clinical characteristics of infections in elderly people admitted to Internal Medicine wards in Spain, as well as the etiology and resistance pattern for the main causal agents, and outcome.

Conditions studied

Infection

Browse trials for

In context

Infections

6,687 studies on the registry are indexed under Infections; 807 are open to participants now.

This study's enrollment of 240 is close to the median of 240 across 2,136 observational studies indexed under Infections.

Browse Infections studies →

Lead sponsor

Wyeth is now a wholly owned subsidiary of Pfizer is the lead sponsor of 472 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

Who can participate

Ages eligible: 65 Years and older
Sexes eligible: All
Accepts healthy volunteers: No
Sampling method: Non-probability sample

Study population

Infected elderly patients treated at Internal Medicine wards in Spanish hospitals

Inclusion criteria

Patients > 65 years of age that are hospitalized in an Internal Medicine ward and have an active infection (skin and soft tissue, intra-abdominal, or respiratory infections) from the community that needs antibiotic treatment
Patients must have at least one sample processed for microbiological diagnosis

Exclusion criteria

Exclusion criteria:

COPD exacerbation
Urinary tract infections
Hospital acquired infections
Other infections not in inclusion criteria

Study design

Observational model: Cohort
Time perspective: Prospective
Enrollment: 240 participants (actual)

Groups and cohorts

1
Infected elderly patients
Other: Clinical record review

Interventions

OtherClinical record review

What researchers measure

Primary outcomes

Prevalence of each kind of infection will be measured from a descriptive point of view, using relative and absolute frequencies.
Time frame: 5 months

Secondary outcomes

Study the etiology and resistance pattern for the main causal agents.
Time frame: 5 months
Describe the demographic features, co-morbidities, concomitant treatment and outcome of patients.
Time frame: 5 months

Study locations

1 site

Mataró, Barcelona 08304, Spain

Updates

Tracking since Sep 25, 2026

No changes since tracking began. The registry record was last updated on Oct 9, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗

Registry details

Key details

Study ID: NCT00900952
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer
First posted: May 13, 2009
Start date: Mar 2009
Primary completion: Jun 2009
Completion: Jun 2009
Last update: Oct 9, 2009

Study contacts

Medical Monitor

study director · Wyeth is now a wholly owned subsidiary of Pfizer

Oversight

Data monitoring committee: No

View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Infections→

Other studies from this sponsor

Wyeth is now a wholly owned subsidiary of Pfizer

Start the discussion